Rigel Pharmaceuticals Inc. (New) (RIGL) is a publicly traded Healthcare sector company. As of July 26, 2026, RIGL trades at $36.74 with a market cap of $679.77M and a P/E ratio of 1.81. RIGL moved -0.11% today. Year to date, RIGL is -14.22%; over the trailing twelve months it is +79.83%. Its 52-week range spans $14.63 to $52.24. Analyst consensus is buy with an average price target of $59.33. Rallies surfaces RIGL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rigel Names Alison Hannah as CMO to Propel R289 Phase 1b and Vepdegestrant Trials: Rigel Pharmaceuticals has appointed board member Alison L. Hannah, M.D. as Executive Vice President and Chief Medical Officer, effective July 1, 2026, with her resigning from the board. She oversaw 40 cancer drug regulatory filings at CytomX and will guide R289 Phase 1b expansion and vepdegestrant trials.
| Metric | Value |
|---|---|
| Price | $36.74 |
| Market Cap | $679.77M |
| P/E Ratio | 1.81 |
| EPS | $20.23 |
| Dividend Yield | 0.00% |
| 52-Week High | $52.24 |
| 52-Week Low | $14.63 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $299.77M |
| Net Income | $364.23M |
| Gross Margin | 93.39% |
3 analysts cover RIGL: 0 strong buy, 2 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $59.33.